SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

BBIO

BridgeBio Pharma, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Brazil approval adds a meaningful new market for acoramidis, reinforcing the drug's global commercial trajectory. Monitor H2 2026 launch execution and any upcoming regulatory decisions in additional countries. The strong Phase 3 data and multiple prior approvals de-risk this expansion, no new clinical data was required.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$68.09
T+0 close · May 6, 2026 · via day close
Latest settled
+17.62%
T+60 · $80.09
Vs SPY
+15.56%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $68.09entry
  2. T+1 · 6mo ago −0.94%α −0.61% · $67.45
  3. T+5 · 6mo ago −3.14%α −4.27% · $65.95
  4. T+20 · 6mo ago −3.83%α −6.61% · $65.48
  5. T+60 · 4mo ago +17.62%α +15.56% · $80.09

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma announced that Brazilian health regulator ANVISA approved acoramidis (BEYONTTRA) for ATTR-CM, adding a sixth major market to its approvals. The drug demonstrated a 42% reduction in composite all-cause mortality and recurrent cardiovascular hospitalization events versus placebo at Month 30 in the Phase 3 ATTRibute-CM study. Commercialization in Brazil, via partner Biopas, is expected to begin in H2 2026, expanding the drug's global reach beyond the U.S., EU, UK, Switzerland, and Japan.

Key Facts

  • ANVISA (Brazil) approved acoramidis (BEYONTTRA) for ATTR-CM in adults.
  • Approval based on Phase 3 ATTRibute-CM study showing 42% reduction in composite ACM and recurrent CVH events at Month 30 vs placebo.
  • 50% reduction in cumulative frequency of CVH events at Month 30 vs placebo.
  • Acoramidis is the first and only approved ATTR-CM treatment in Brazil with a label specifying near-complete (≥90%) TTR stabilization.
  • Commercialization in Brazil via Biopas (Swixx BioPharma) expected to begin in H2 2026.
  • Acoramidis previously approved in U.S. (Nov 2024), EU (Feb 2025), Japan (Mar 2025), UK (Apr 2025), and Switzerland.
  • BridgeBio market cap ~$13.5B; analyst consensus 97% bullish (29 of 30 analysts Buy/Strong Buy).

Financial Impact

Expands total addressable market for acoramidis to Brazil, the largest Latin American pharmaceutical market. No specific revenue guidance provided; prior U.S. approval in Nov 2024 and EU/Japan approvals in early 2025 already established commercial base.

revenuemarket access

Risk Factors

  • Commercialization in Brazil depends on partner Biopas execution; any delays in H2 2026 launch could disappoint.
  • Pricing and reimbursement negotiations in Brazil may limit initial uptake.
  • Competition from Pfizer's tafamidis (Vyndamax) and other emerging ATTR-CM therapies in the Brazilian market.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3288693

Track record

38 reports on BBIO

Performance horizon

10 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026